UPDATE 1-Roche says Tecentriq combination cuts lung cancer risk

ZURICH, Nov 20 (Reuters) - Roche got a double dose of positive trial news on Monday, with its immunotherapy Tecentriq mixed with other drugs succeeding against lung cancer in one study and its haemophilia drug Hemlibra notching a win in a new group of patients.